Speaker Profile

Honorio Silva

Vice-President, Inter American Foundation for Clinical Research Director, Pan American Federation of Associations of Medical Schools Caracas, Venezuela

Dr. Silva's professional career has focused on fostering clinical research and medical education with particular emphasis on emerging countries, in addition to serving the pharmaceutical industry, academia and various professional associations. After 30-years of service with Pfizer Inc, Dr. Silva retired in 2008 as Vice President, Science and Medical Professional Development, within the External Medical Affairs group. Dr. Silva began his career as Medical Director, Pfizer - Venezuela, his native country, before transferring to Pfizer's New York headquarters. Dr. Silva also served as Vice President, Medical and Regulatory Affairs, Japan, Asia, Africa & Latin America and Director/Team Leader Medical Operations, Latin America & Canada.

His medical education was received in Argentina, with postgraduate training in internal medicine and clinical pharmacology in Argentina and Venezuela, respectively. His former academic affiliations and titles include: Assistant Professor of Pharmacology, Universidad Central de Venezuela; Associate Director, Clinical Pharmacology and Arterial Hypertension Unit, Vargas Hospital, Caracas and Senior Scientist, HST Center for Experimental Pharmacology and Therapeutics at Harvard-MIT. Dr. Silva has authored or co-authored more than 90 publications on cardiovascular disease, arterial hypertension, infectious disease and clinical pharmacology and co-edited two books on the latter discipline. While serving on the Boards of, and as President for both the Venezuelan Society for Clinical Pharmacology and the Venezuelan Society of Pharmacology, he pioneered CPD and e-learning programs in Venezuela and Latin America. He also organized the development of clinical trials and epidemiological studies across continents.
Dr. Silva has received several awards for his contributions to clinical research, medical education and pharmaceutical development.

Sign Up for Our Newsletter